User login
Article Type
Changed
Tue, 05/03/2022 - 16:00
Display Headline
Updates in Specialty Care
Article PDF
Issue
Federal Practitioner - 28(4)
Publications
Topics
Page Number
39
Legacy Keywords
diabetes, clinical practice guidelines, GRADE instrument, comorbid conditions, glycemic targets, A1c tests, estimated average glucose, glucose-based tests, glycemic control, hemolytic anemia, iron deficiency anemia, severe chronic kidney disease, National Glycohemoglobin Standardization Program, coefficient of variation, mean plasma glucose, Working Group, glucose-lowering agents, Action to Control Cardiovascular Risk in Diabetes, VA Diabetes Trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluationdiabetes, clinical practice guidelines, GRADE instrument, comorbid conditions, glycemic targets, A1c tests, estimated average glucose, glucose-based tests, glycemic control, hemolytic anemia, iron deficiency anemia, severe chronic kidney disease, National Glycohemoglobin Standardization Program, coefficient of variation, mean plasma glucose, Working Group, glucose-lowering agents, Action to Control Cardiovascular Risk in Diabetes, VA Diabetes Trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation
Sections
Article PDF
Article PDF
Issue
Federal Practitioner - 28(4)
Issue
Federal Practitioner - 28(4)
Page Number
39
Page Number
39
Publications
Publications
Topics
Article Type
Display Headline
Updates in Specialty Care
Display Headline
Updates in Specialty Care
Legacy Keywords
diabetes, clinical practice guidelines, GRADE instrument, comorbid conditions, glycemic targets, A1c tests, estimated average glucose, glucose-based tests, glycemic control, hemolytic anemia, iron deficiency anemia, severe chronic kidney disease, National Glycohemoglobin Standardization Program, coefficient of variation, mean plasma glucose, Working Group, glucose-lowering agents, Action to Control Cardiovascular Risk in Diabetes, VA Diabetes Trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluationdiabetes, clinical practice guidelines, GRADE instrument, comorbid conditions, glycemic targets, A1c tests, estimated average glucose, glucose-based tests, glycemic control, hemolytic anemia, iron deficiency anemia, severe chronic kidney disease, National Glycohemoglobin Standardization Program, coefficient of variation, mean plasma glucose, Working Group, glucose-lowering agents, Action to Control Cardiovascular Risk in Diabetes, VA Diabetes Trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation
Legacy Keywords
diabetes, clinical practice guidelines, GRADE instrument, comorbid conditions, glycemic targets, A1c tests, estimated average glucose, glucose-based tests, glycemic control, hemolytic anemia, iron deficiency anemia, severe chronic kidney disease, National Glycohemoglobin Standardization Program, coefficient of variation, mean plasma glucose, Working Group, glucose-lowering agents, Action to Control Cardiovascular Risk in Diabetes, VA Diabetes Trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluationdiabetes, clinical practice guidelines, GRADE instrument, comorbid conditions, glycemic targets, A1c tests, estimated average glucose, glucose-based tests, glycemic control, hemolytic anemia, iron deficiency anemia, severe chronic kidney disease, National Glycohemoglobin Standardization Program, coefficient of variation, mean plasma glucose, Working Group, glucose-lowering agents, Action to Control Cardiovascular Risk in Diabetes, VA Diabetes Trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation
Sections
Article Source
PURLs Copyright
Inside the Article
Article PDF Media
Document